Last update 06 Jul 2026
Zhejiang Carbiogene Therapeutics Co. Ltd.

Zhejiang Carbiogene Therapeutics Co. Ltd.

Private Company|2016|Zhejiang Sheng, China|

Overview

Basic Info

Introduction
Carbiogene Therapeutics Co. Ltd. is a high-tech biomedical innovation enterprise jointly founded by well-known scientists at home and abroad, integrating research and development, production and sales. It is a "5050 plan" enterprise and a national high-tech enterprise introduced by the Zhejiang Government of China. Carbiogene Therapeutics has established an industry pattern with new anti-tumor immunotherapy products (new generation CAR-T, AI CAR-T, CAR-NK) as the leading, retroviral vector technology platform, new DC vaccine, immune cell and stem cell biological resource bank, medical laboratory center and digital medical health platform. The company is committed to promoting the clinical application of a new generation of tumor immune precision therapy technology.

Tags

Neoplasms
Immune System Diseases
Digestive System Disorders
CAR-T
Autologous CAR-T
Cell therapy

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Top 5 Drug TypeCount
CAR-T6
Autologous CAR-T1
Cell therapy1
Top 5 TargetCount
BCMA(B-cell maturation protein)1

Corporation Tree

Boost your research with our corporation tree data.
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 24 Aug 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Discovery
1
4
Preclinical
Phase 1
3
1
Other
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
CBG002
( BCMA )
Refractory Multiple Myeloma
More
Phase 1
CBG-166
Advanced Hepatocellular Carcinoma
More
Phase 1
CBG-131
CLDN18.2 positive Pancreatic Cancer
More
Early Phase 1
CBG-139
Acute Myeloid Leukemia
More
Preclinical
CBG-318
Multiple Myeloma
More
Preclinical
Login to view more data

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
Unearth financing trends to validate and advance investment opportunities.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free